CoChat
Sign Up
Cited by 156Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and LipoproteinsChronic Disease Management Strategies

Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017

Open access
Li, Huixian, Lu, Wanhong, Wang, Ani, Jiang, Hongli, Lyu, Jun·2021·Journal of Diabetes Investigation
DOI 10.1111/jdi.13355PMC PMC7926234
Open this paper in CoChat — free accountOpen PDF

Abstract

Aims/Introduction: Type 2 diabetes mellitus has been a leading cause of chronic kidney disease (CKD), with a heterogeneous distribution worldwide. Optimal healthcare planning requires an understanding of how the burden of CKD as a result of type 2 diabetes mellitus has changed over time and geographic location, as well as the potential roles of sociodemographic, clinical and behavioral factors in these changes. Materials and Methods: We used the Global Burden of Disease data from 1990 to 2017 at the global, regional and national levels to investigate changes in the incidence, death and disability‐adjusted life years of CKD as a result of type 2 diabetes mellitus, incorporating both epidemiological research and risk factor monitoring. Results: The incident cases of CKD as a result of type 2 diabetes mellitus worldwide in 2017 had increased by 74% compared with 1990; total disability‐adjusted life years had increased by 113%, mainly attributable to population expansion and demographic transition. The Sociodemographic Index was significantly and negatively correlated with overall CKD as a result of type 2 diabetes mellitus burden. However, in 82 countries and territories, the burden was not alleviated in parallel with socioeconomic development. Conclusions: CKD as a result of type 2 diabetes mellitus has been the main contributor to the increasing burden of CKD over the past several decades. We suggest a more pragmatic approach focusing on early diagnosis, primary care and adequate follow up to reduce mortality and the long‐term burden in low‐to‐middle Sociodemographic Index regions. Interventions should address high systolic blood pressure, as well as overweight and obesity problems, especially in high‐income regions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdi.13355

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The incidence of CKD in people with diabetes has decreased over the last decade but remains high in the U.S. and around the world.

    “The incidence of CKD in people with diabetes has decreased over the last decade but remains high in the U.S. (3) and around the world (7).”

    From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [7]

    The Results section reports that the global age-standardized incidence rate of CKD due to type 2 diabetes fell from 1990 to 2017, while 2.35 million new cases occurred worldwide in 2017. This supports a substantial continuing global burden, but the paper does not establish a decline specifically over the last decade; it reports that the worldwide number of new cases increased over the full study period. The U.S. portion of the citing sentence is attached to a different citation. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. [1]Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med 2016; 375: 905– 906. 27579659
  2. [2]Fraser SDS, Roderick PJ. Kidney disease in the Global Burden of Disease Study 2017. Nat Rev Nephrol 2019; 15: 193– 194. 30723305
  3. [3]Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018; 94: 567– 581. 30078514
  4. [4]Jager KJ, Fraser SDS. The ascending rank of chronic kidney disease in the global burden of disease study. Nephrol Dial Transplant 2017; 32(suppl_2): ii121– ii128. 28201666
  5. [5]Wang F, Yang C, Long J, et al. Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK‐NET). Kidney Int 2019; 95: 501– 505. 30784660
  6. [6]Global, regional, and national burden of chronic kidney disease, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395: 709– 733. 32061315 PMC7049905
  7. [7]Collaboration NCDRF. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population‐based studies with 4.4 million participants. Lancet 2016; 387: 1513– 1530. 27061677 PMC5081106
  8. [8]GBD 2017 Disease and Injury Incidence and Prevalence Collaborator. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789– 1858. 30496104 PMC6227754
  9. [10]GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability‐adjusted life‐years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1859– 1922. 30415748 PMC6252083
  10. [11]GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1995– 2051. 30496106 PMC6227915
  11. [12]Gao S, Yang WS, Bray F, et al. Declining rates of hepatocellular carcinoma in urban Shanghai: incidence trends in 1976–2005. Eur J Epidemiol. 2012; 27: 39– 46. 22160277 PMC5477645
  12. [13]GBD 2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet 2017; 390: 231– 266. 28528753 PMC5528124
  13. [15]Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017; 6: CD010137. 28594069 PMC6481869
  14. [16]Andresdottir G, Jensen ML, Carstensen B, et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 2014; 37: 1660– 1667. 24623028
  15. [17]Gao B, Wu S, Wang J, et al. Clinical features and long‐term outcomes of diabetic kidney disease ‐ A prospective cohort study from China. J Diabetes Complicat 2019; 33: 39– 45. 30482493
  16. [18]Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225– 232. 12472787
  17. [19]de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532– 2539. 21693741 PMC3731378
  18. [20]Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 2016; 316: 602– 610. 27532915 PMC5444809
  19. [21]Dabelea D, Mayer‐Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311: 1778– 1786. 24794371 PMC4368900
  20. [22]Mayer‐Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med 2017; 376: 1419– 1429. 28402773 PMC5592722
  21. [23]Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010; 8: 29. 20969750 PMC2984379
  22. [24]Thomas B. The global burden of diabetic kidney disease: time trends and gender gaps. Curr Diab Rep 2019; 19: 18. 30826889
  23. [25]Harris DC, Dupuis S, Couser WG, et al. Training nephrologists from developing countries: does it have a positive impact? Kidney Int Suppl 2011; 2012: 275– 278. PMC4089592 25018942
  24. [26]Cervantes L, Tuot D, Raghavan R, et al. Association of Emergency‐Only vs Standard Hemodialysis With Mortality and Health Care Use Among Undocumented Immigrants With End‐stage Renal Disease. JAMA Intern Med. 2018; 178: 188– 195. 29255898 PMC5838789
  25. [27]Osman MA, Alrukhaimi M, Ashuntantang GE, et al. Global nephrology workforce: gaps and opportunities toward a sustainable kidney care system. Kidney Int Suppl 2011; 2018: 52– 63. PMC6336213 30675439
  26. [28]Bello AK, Johnson DW, Feehally J, et al. Global Kidney Health Atlas (GKHA): design and methods. Kidney Int Suppl 2011; 2017: 145– 153. PMC6341016 30675429
  27. [29]Htay H, Alrukhaimi M, Ashuntantang GE, et al. Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. Kidney Int Suppl 2011; 2018: 64– 73. PMC6336224 30675440
  28. [30]Crews DC, Bello AK, Saadi G. Burden, access, and disparities in kidney disease. Kidney Int 2019; 95: 242– 248. 30665560
  29. [31]Karopadi AN, Mason G, Rettore E, et al. Cost of peritoneal dialysis and haemodialysis across the world. Nephrol Dial Transplant 2013; 28: 2553– 2569. 23737482
  30. [32]Muralidharan A, White S. The need for kidney transplantation in low‐ and middle‐income countries in 2012: an epidemiological perspective. Transplantation 2015; 99: 476– 481. 25680089
  31. [33]Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013; 24: 302– 308. 23362314 PMC3559486
  32. [34]Collaborators GBDRF. Global regional and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1923– 1994. 30496105 PMC6227755
  33. [35]Liao D, Ma L, Liu J, et al. Cigarette smoking as a risk factor for diabetic nephropathy: a systematic review and meta‐analysis of prospective cohort studies. PLoS One 2019; 14: e0210213. 30716100 PMC6361430
  34. [37]Chin WS, Chang YK, Huang LF, et al. Effects of long‐term exposure to CO and PM2.5 on microalbuminuria in type 2 diabetes. Int J Hyg Environ Health 2018; 221: 602– 608. 29706436
  35. [38]Collaborators GBDO, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017; 377: 13– 27. 28604169 PMC5477817
  36. [39]Lambers Heerspink HJ, Navis G, Ritz E. Salt intake in kidney disease–a missed therapeutic opportunity? Nephrol Dial Transplant 2012; 27: 3435– 3442. 22942175

Cited by

Sorted by citations

Authors
Li, H., Lu, W., Wang, A., Jiang, H., & Lyu, J.
Affiliations
First Affiliated Hospital of Xi'an Jiaotong University (CN)
Corresponding author
Lyu, Jun
ORCID
Venue
Journal of Diabetes Investigation
Publisher
Wiley
Published
2020-08-17
Volume
12
Issue
3
Pages
346-356
ISSN
  • 2040-1116 (ISSN-L)
  • 2040-1124
DOI
10.1111/jdi.13355
PMC
PMC7926234
OpenAlex
W3040808389
Cited by
156
References
3
Citations by year
2026: 20 · 2025: 36 · 2024: 30 · 2023: 32 · 2022: 25 · 2021: 9 · 2020: 4
FWCI
11.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Diabetes Investigation (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
Keywords
chronic kidney disease, type 2 diabetes, disease burden, disability-adjusted life years, incidence trends, mortality, socio-demographic index, socio-economic development, systolic blood pressure, obesity, early diagnosis, global burden of disease
MeSH terms
Global Burden of Disease, Diabetes Mellitus, Type 2, Female, Humans, Male, Risk Factors, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review